Limerick BioPharma, Inc.

Limerick BioPharma is dedicated to developing compounds that, when used with both marketed and investigational drugs, significantly improve the quality of patients’ lives. These compounds minimize toxic side effects at non-targeted vulnerable organs and maintain or enhance a drug’s desired effects.

Through its efficient discovery and development strategy implemented with leading academics and other collaborators, Limerick has created a clinical pipeline of proprietary Efflux Pump Activators. These proprietary assets have been successfully paired with drug ligands in preclinical and clinical trials to improve tissue distribution. The effects include enhanced pharmacokinetic and pharmacodynamic properties and reduced drug side effects.

Limerick’s proprietary activators target a broad range of therapeutic drug classes including immunosuppressants, opioids, immunomodulators, selective estrogens receptor modulators, and psychotropics.